RE:RE:RE:RE:RE:RE:Q&A indicates LSA has brought some good new investors There are some many targets on cancer cells and so many drugs going after those targets it's interesting to hear them really try to differentiate this program based on the specialness of SORT as a "scavenger". There was one question about who else is studying SORT and why nobody else is really going after it. I think that it's reasonable to wonder whether SORT is a "marginal" receptor because of that. I thought they handled that well, I guess I'm starting to believe in SORT as something potentially special not just another target.
SPCEO1 wrote: Like Wino, I asked a commercially oriented question that was ignored. I suspect LSA wanted to keep this one focused on science.
qwerty22 wrote: That was one thing missing any talk about commercial, comparable companies, ADC market etc
Wino115 wrote: I think we snuffed out your's and JFMs questions -- the 2nd MOA one and the imaging one.
Mine didn't get asked as it was to crass I guess -- what do you think is the commercial opportunity for this platform? and , do you think clinics will use it at the 2L and 3L level if sortilin is expressed enough?
qwerty22 wrote: I got two Qs asked
Wino115 wrote:
Or JFM Scarlet and QWERTY stuffed the Q&A box.
SPCEO1 wrote: Very scientific questions indicate to me that US based institutions are indeed on this call - a very good sign for LSA's capabilities.